Abp-788.mp4 -

ARX788 is a site-specific ADC designed to target and HER2-low cancers. Unlike traditional therapies, it uses a unique non-natural amino acid technology to link a potent toxin directly to an antibody, ensuring the "payload" is delivered specifically to cancer cells while sparing healthy tissue. 1. Clinical Applications & Efficacy

: Ongoing research is exploring its use in patients with lower levels of HER2 expression, who previously had limited targeted therapy options. 2. Mechanism of Action ABP-788.mp4

The "guide" in the video likely explains the : ARX788 is a site-specific ADC designed to target

: Uses a highly stable oxime bond to prevent the premature release of the toxin into the bloodstream, which reduces systemic side effects. Clinical Applications & Efficacy : Ongoing research is

: Recent data from the ACE-Breast-06 study showed that ARX788 can cross the blood-brain barrier, providing a 25% objective response rate for patients with active brain metastases.

If the video discusses trial results, it likely highlights these key areas: